source
- Swiss biotech Windward Bio raises $175 million in IPO to fund lung-drug development and test Tezspire competitorWindward Bio, a Swiss immune‑drug developer, completed a $175 million initial public offering, selling about 10.3 million shares at $17 each. The company began trading on the exchange under the tic…
- New organ donation rules criticized for pressuring grieving familiesA neurologist at Oregon Health & Science University recounts the case of a 22-year-old woman who was declared brain dead after a traffic accident and became a donor. He describes the intensive moni…